Literature DB >> 25964311

Programmed death ligand 1 (PD-L1) as an immunotherapy target in patients with glioblastoma.

Gordana Vlahovic1, Peter E Fecci1, David Reardon1, John H Sampson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25964311      PMCID： PMC4490880          DOI： 10.1093/neuonc/nov071

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

1.  Cervical lymphatics, the blood-brain barrier and the immunoreactivity of the brain: a new view.

Authors:  H F Cserr; P M Knopf
Journal:  Immunol Today       Date:  1992-12

Review 2.  CNS immune privilege: hiding in plain sight.

Authors:  Monica J Carson; Jonathan M Doose; Benoit Melchior; Christoph D Schmid; Corinne C Ploix
Journal:  Immunol Rev       Date:  2006-10       Impact factor: 12.988

Review 3.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

4.  Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

Authors:  M R Zalutsky; R P Moseley; H B Coakham; R E Coleman; D D Bigner
Journal:  Cancer Res       Date:  1989-05-15       Impact factor: 12.701

5.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

6.  Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma.

Authors:  Andrew T Parsa; James S Waldron; Amith Panner; Courtney A Crane; Ian F Parney; Jeffrey J Barry; Kristine E Cachola; Joseph C Murray; Tarik Tihan; Michael C Jensen; Paul S Mischel; David Stokoe; Russell O Pieper
Journal:  Nat Med       Date:  2006-12-10       Impact factor: 53.440

7.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

8.  Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages.

Authors:  Orin Bloch; Courtney A Crane; Rajwant Kaur; Michael Safaee; Martin J Rutkowski; Andrew T Parsa
Journal:  Clin Cancer Res       Date:  2013-04-23       Impact factor: 12.531

Review 9.  Oncology meets immunology: the cancer-immunity cycle.

Authors:  Daniel S Chen; Ira Mellman
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

10.  Molecular pathways: next-generation immunotherapy--inhibiting programmed death-ligand 1 and programmed death-1.

Authors:  Daniel S Chen; Bryan A Irving; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531
View more
  14 in total

Review 1.  Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Authors:  Jacob S Young; Fara Dayani; Ramin A Morshed; Hideho Okada; Manish K Aghi
Journal:  World Neurosurg       Date:  2019-01-21       Impact factor: 2.104

2.  Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma.

Authors:  Rimas V Lukas; Jordi Rodon; Kevin Becker; Eric T Wong; Kent Shih; Mehdi Touat; Marcella Fassò; Stuart Osborne; Luciana Molinero; Carol O'Hear; William Grossman; Joachim Baehring
Journal:  J Neurooncol       Date:  2018-08-02       Impact factor: 4.130

Review 3.  Circulating biomarkers for gliomas.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurol       Date:  2015-09-15       Impact factor: 42.937

Review 4.  Prospects of immune checkpoint modulators in the treatment of glioblastoma.

Authors:  Matthias Preusser; Michael Lim; David A Hafler; David A Reardon; John H Sampson
Journal:  Nat Rev Neurol       Date:  2015-08-11       Impact factor: 42.937

5.  Solasonine inhibits glioma growth through anti-inflammatory pathways.

Authors:  Xun Wang; Shuang Zou; Yu-Long Lan; Jin-Shan Xing; Xiao-Qiang Lan; Bo Zhang
Journal:  Am J Transl Res       Date:  2017-09-15       Impact factor: 4.060

Review 6.  The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.

Authors:  Ryota Tamura; Toshihide Tanaka; Yasuharu Akasaki; Yuichi Murayama; Kazunari Yoshida; Hikaru Sasaki
Journal:  Med Oncol       Date:  2019-11-11       Impact factor: 3.064

7.  Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.

Authors:  Cassie Kline; S John Liu; Sai Duriseti; Anuradha Banerjee; Theodore Nicolaides; Shannon Raber; Nalin Gupta; Daphne Haas-Kogan; Steve Braunstein; Sabine Mueller
Journal:  J Neurooncol       Date:  2018-09-11       Impact factor: 4.130

8.  Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.

Authors:  Peng-Fei Wang; Hong-Wang Song; Hong-Qing Cai; Ling-Wei Kong; Kun Yao; Tao Jiang; Shou-Wei Li; Chang-Xiang Yan
Journal:  Oncotarget       Date:  2017-07-25

Review 9.  Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma?

Authors:  Matthias Preusser; Anna S Berghoff; Wolfgang Wick; Michael Weller
Journal:  Clin Neuropathol       Date:  2015 Nov-Dec       Impact factor: 1.368

10.  A regulatory role for the co-chaperone FKBP51s in PD-L1 expression in glioma.

Authors:  Paolo D'Arrigo; Michele Russo; Anna Rea; Martina Tufano; Elia Guadagno; Maria Laura Del Basso De Caro; Roberto Pacelli; Felix Hausch; Stefania Staibano; Gennaro Ilardi; Silvia Parisi; Maria Fiammetta Romano; Simona Romano
Journal:  Oncotarget       Date:  2017-07-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.